488 related articles for article (PubMed ID: 32343968)
1. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
Radbel J; Narayanan N; Bhatt PJ
Chest; 2020 Jul; 158(1):e15-e19. PubMed ID: 32343968
[TBL] [Abstract][Full Text] [Related]
2. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
[TBL] [Abstract][Full Text] [Related]
3. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
Stephen S; Park YA; Chrysostomou A
Nephrology (Carlton); 2020 Nov; 25(11):845-849. PubMed ID: 32776624
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 and QT interval prolongation: more than just drug toxicity?
Merino JL; Martínez-Cossiani M; Iniesta A; Escobar C; Rey JR; Castrejón-Castrejón S
Europace; 2020 Oct; 22(10):1479. PubMed ID: 32441761
[No Abstract] [Full Text] [Related]
6. A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Cai S; Sun W; Li M; Dong L
Clin Rheumatol; 2020 Sep; 39(9):2797-2802. PubMed ID: 32562070
[TBL] [Abstract][Full Text] [Related]
7. Fatal SARS-CoV-2 infection in a renal transplant recipient.
Dirim AB; Demir E; Ucar AR; Garayeva N; Safak S; Oto OA; Yazici H; Alibeyoglu AM; Orhun G; Cagatay AA; Turkmen A
CEN Case Rep; 2020 Nov; 9(4):409-412. PubMed ID: 32564306
[TBL] [Abstract][Full Text] [Related]
8. Three Cases of COVID-19 Disease With Colonic Manifestations.
Sattar Y; Connerney M; Rauf H; Saini M; Ullah W; Mamtani S; Syed U; Luddington S; Walfish A
Am J Gastroenterol; 2020 Jun; 115(6):948-950. PubMed ID: 32427677
[No Abstract] [Full Text] [Related]
9. Tocilizumab for severe COVID-19: a systematic review and meta-analysis.
Lan SH; Lai CC; Huang HT; Chang SP; Lu LC; Hsueh PR
Int J Antimicrob Agents; 2020 Sep; 56(3):106103. PubMed ID: 32712333
[TBL] [Abstract][Full Text] [Related]
10. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
Gokhale Y; Mehta R; Kulkarni U; Karnik N; Gokhale S; Sundar U; Chavan S; Kor A; Thakur S; Trivedi T; Kumar N; Baveja S; Wadal A; Kolte S; Deolankar A; Pednekar S; Kalekar L; Padiyar R; Londhe C; Darole P; Pol S; Gokhe SB; Padwal N; Pandey D; Yadav D; Joshi A; Badgujar H; Trivedi M; Shah P; Bhavsar P
BMC Infect Dis; 2021 Mar; 21(1):241. PubMed ID: 33673818
[TBL] [Abstract][Full Text] [Related]
12. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
13. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia.
Capra R; De Rossi N; Mattioli F; Romanelli G; Scarpazza C; Sormani MP; Cossi S
Eur J Intern Med; 2020 Jun; 76():31-35. PubMed ID: 32405160
[TBL] [Abstract][Full Text] [Related]
14. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
16. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
17. A histopathological observation regarding the possibility of hemophagocytic lymphohistiocytosis in COVID-19 patients.
Abdollahi A; Beigmohammadi MT; Safaei M; Mehrtash V; Jafarzadeh B
J Gastrointestin Liver Dis; 2020 Sep; 29(3):475-476. PubMed ID: 32919429
[No Abstract] [Full Text] [Related]
18. Left ventricular dysfunction in COVID-19: A diagnostic issue.
Jacquet-Lagrèze M; Riad Z; Hugon-Vallet E; Ferraris A; Fellahi JL
Anaesth Crit Care Pain Med; 2020 Jun; 39(3):393-394. PubMed ID: 32562808
[No Abstract] [Full Text] [Related]
19. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
20. Could hemophagocytic lymphohistiocytosis be the core issue of severe COVID-19 cases?
Opoka-Winiarska V; Grywalska E; Roliński J
BMC Med; 2020 Jul; 18(1):214. PubMed ID: 32664932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]